Exploiting human herpesvirus immune evasion for therapeutic gain: Potential and pitfalls

Immunology and Cell Biology

Volumn 89, Issue 3, 2011, Pages 359-366

  Horst, Daniëlle ^a,b   Ressing, Maaike E ^a,b   Wiertz, Emmanuel J H J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

gene therapy; herpesviruses; immune evasion; MHC Class I antigen presentation; vaccination; virus stealth technology

Indexed keywords

G 207; HERPES VACCINE; HERPESVIRUS VECTOR; INITIATION FACTOR 2ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN KINASE R; VARICELLA ZOSTER VACCINE; VIRUS DNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DNA SYNTHESIS; EPSTEIN BARR VIRUS; GENE THERAPY; GRAFT REJECTION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; TRANSPLANTATION TOLERANCE; VACCINATION; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS; VIRUS INTERFERENCE; VIRUS REACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VACCINATION;

HERPESVIRIDAE;

EID: 79952814744     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.129     Document Type: Review

References (126)

1. Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ, Minson AC et al. Theorder herpesvirales. Arch Virol 2009; 154: 171-177.
2. Wiertz EJ, Mukherjee S, Ploegh HL. Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997; 3: 116-123. (Pubitemid 28119277)
3. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002; 54: 527-542. (Pubitemid 35435511)
4. Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat Immunol 2002; 3: 1019-1025. (Pubitemid 35363652)
5. Lilley BN, Ploegh HL. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 2005; 207: 126-144. (Pubitemid 41415013)
6. Griffin BD, Verweij MC, Wiertz EJ. Herpesviruses and immunity: the art of evasion. Vet Microbiol 2010; 143: 89-100.
7. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996; 5: 103-114. (Pubitemid 26301087)
8. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line 220. Immunity 1998; 8: 221-231. (Pubitemid 28123749)
9. Dick TP, Bangia N, Peaper DR, Cresswell P. Disulfide bond isomerization and the assembly of MHC class I-peptide complexes. Immunity 2002; 16: 87-98. (Pubitemid 34143219)
10. Dong G, Wearsch PA, Peaper DR, Cresswell P, Reinisch KM. Insights into MHCclass I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase hetero-dimer. Immunity 2009; 30: 21-32.
11. Peaper DR, Cresswell P. The redox activity of ERp57 is not essential for its functions in MHC class I peptide loading. Proc Natl Acad Sci USA 2008; 105: 10477-10482.
12. Wearsch PA, Cresswell P. Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin-ERp57 heterodimer. Nat Immunol 2007; 8: 873-881. (Pubitemid 47099039)
13. Park B, Lee S, Kim E, Cho K, Riddell SR, Cho S et al. Redox regulation facilitates optimal peptide selection by MHC class I duringantigen processing. Cell 2006; 127: 369-382. (Pubitemid 44572373)
14. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol 2010; 10: 403-414.
15. Tigges MA, Leng S, Johnson DC, Burke RL. Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion hostshutofffunctionsaredisabled. J Immunol 1996; 156: 3901-3910.
16. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, Ressing ME et al. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 2008; 82: 2385-2393. (Pubitemid 351293539)
17. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 2007; 104: 3366-3371. (Pubitemid 46364165)
18. Glaunsinger B, Ganem D. Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol Cell 2004; 13: 713-723. (Pubitemid 38368128)
19. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomega-lovirus US11 gene productdislocates MHC class I heavychainsfrom theendoplasmic reticulum to the cytosol. Cell 1996; 84: 769-779. (Pubitemid 26094206)
20. Wiertz EJHJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996; 384: 432-438. (Pubitemid 26414653)
21. Park B, Spooner E, Houser BL, Strominger JL, Ploegh HL. The HCMV membrane glycoprotein US10 selectivelytargets HLA-G for degradation. J Exp Med 2010; 207: 2033-2041.
22. Glosson NL, Hudson AW. Human herpesvirus-6Aand-6B encodeviral immunoevasins that downregulate class I MHC molecules. Virology 2007; 365: 125-135. (Pubitemid 46907238)
23. Hudson AW, Howley PM, Ploegh HL. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibilitycomplexclass I molecules to lysosomes. J Virol 2001; 75:12347-12358. (Pubitemid 33115907)
24. Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 2009; 5: e 1000255.
25. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancingtheir endocytosis. Proc Natl Acad Sci USA 2000; 97: 8051-8056. (Pubitemid 30460771)
26. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Down regulation of majorhistocompat-ibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 2000; 74: 5300-5309. (Pubitemid 30313872)
27. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella-zoster virus retains major histocompatibilitycomplexclass I proteins intheGolgi compartment of infected cells. J Virol 2001; 75: 4878-4888. (Pubitemid 32381530)
28. Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR. Downregulation ofclass I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and-independent mechanisms. J Virol 2007; 81: 9034-9049. (Pubitemid 47311447)
29. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavychains. Proc Natl Acad Sci USA 1996; 93: 11327-11333. (Pubitemid 26347121)
30. Park B, Kim Y, Shin J, Lee S, Cho K, Fruh K et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 2004; 20: 71-85. (Pubitemid 38134295)
31. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA 1996; 93: 10990-10995. (Pubitemid 26333105)
32. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
33. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616-12621. (Pubitemid 27492577)
34. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barrvirus-encoded EBNA1. Science 2003; 301: 1371-1374. (Pubitemid 37075811)
35. Zaldumbide A, Ossevoort M, Wiertz EJ, Hoeben RC. In cis inhibition of antigen processing bythe latency-associated nuclearantigen I of Kaposi sarcoma herpesvirus. Mol Immunol 2007; 44: 1352-1360. (Pubitemid 44415957)
36. Ahn K, Meyer TH, Uebel S, Sempe P, Djaballah H, Yang Y et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J 1996; 15: 3247-3255. (Pubitemid 26231930)
37. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, Tampe R et al. Aviral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415-418.
38. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J et al. Herpes simplexvirusturns off the TAP to evade host immunity. Nature 1995; 375: 411-415.
39. Tomazin R, Hill AB, Jugovic P, York I, van Endert P, Ploegh HL et al. Stable bindingof the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 1996; 15: 3256-3266. (Pubitemid 26231931)
40. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC Acytosolic herpes simplexvirus protein inhibitsantigen presentationtoCD8+T lymphocytes. Cell 1994; 77: 525-535.
41. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997; 6: 613-621. (Pubitemid 27239352)
42. Hengel H, Koopmann JO, Flohr T, Muranyi W, Goulmy E, Hammerling GJ et al.Aviral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997; 6: 623-632. (Pubitemid 27239353)
43. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J 2001; 20: 387-396. (Pubitemid 32126975)
44. Kyritsis C, Gorbulev S, Hutschenreiter S, Pawlitschko K, Abele R, Tampe R. Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. J Biol Chem 2001; 276: 48031-48039.
45. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. Thehuman cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent pep-tidetranslocation. Proc Natl Acad Sci USA 1997; 94: 6904-6909. (Pubitemid 27281963)
46. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007; 204: 1863-1873. (Pubitemid 47236322)
47. Bennett NJ, May JS, Stevenson PG. Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol 2005; 3: e120.
48. Boname JM, Stevenson PG. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 2001; 15: 627-636. (Pubitemid 33016447)
49. Stevenson PG, May JS, Smith XG, Marques S, Adler H, Koszinowski UH et al. K3-mediated evasion of CD8(+) Tcells aids amplification of a latent gamma-herpesvirus. Nat Immunol 2002; 3: 733-740.
50. Snyder CM, Allan JE, Bonnett EL, Doom CM, Hill AB. Cross-presentation of a spread-defective MCMVissufficientto primethe majorityofvirus- specificCD8+Tcells. PLoS One 2010; 5: e 9681.
51. Munks MW, Pinto AK, Doom CM, Hill AB. Viral interferencewith antigen presentation does not alter acute or chronic CD8Tcell immunodominance in murine cytomegalo-virus infection. J Immunol 2007; 178: 7235-7241. (Pubitemid 46847449)
52. Gold MC, Munks MW, Wagner M, McMahon CW, Kelly A, Kavanagh DG et al. Murine cytomegalovirus interferencewith antigen presentation has littleeffectonthesizeor the effector memory phenotype of the CD8T cell response. J Immunol 2004; 172: 6944-6953. (Pubitemid 38669134)
53. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D et al. Evasion of CD8+ Tcells is critical for superinfection by cytomegalovirus. Science 2010; 328: 102-106.
54. Remeijer L, Maertzdorf J, Buitenwerf J, Osterhaus AD, Verjans GM. Corneal herpes simplex virus type 1 superinfection in patients with recrudescent herpetic keratitis. Invest Ophthalmol Vis Sci 2002; 43: 358-363. (Pubitemid 34113215)
55. Meyer-Konig U, Ebert K, Schrage B, Pollak S, Hufert FT. Simultaneous infection of healthy people with multiple human cytomegalovirus strains. Lancet 1998; 352: 1280-1281. (Pubitemid 28470344)
56. Srivastava G, Wong KY, Chiang AK, Lam KY, Tao Q. Coinfection of multiple strains of Epstein-Barr virus in immunocompetent normal individuals: reassessment of the viral carrier state. Blood 2000; 95: 2443-2445. (Pubitemid 30167749)
57. Pande NT, Powers C, Ahn K, Fruh K. Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11. J Virol 2005; 79: 5786-5798. (Pubitemid 40548247)
58. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-299.
59. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, rando-mized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749-1753. (Pubitemid 351411934)
60. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27: 159-176.
61. Arvin AM, Gershon AA. Live attenuated varicella vaccine. Annu Rev Microbiol 1996; 50: 59-100. (Pubitemid 26337459)
62. Read GS, Frenkel N. Herpes simplex virus mutants defective in the virion-associated shutoff of host polypeptide synthesis and exhibiting abnormal synthesis of alpha (immediate early) viral polypeptides. J Virol 1983; 46: 498-512. (Pubitemid 13130022)
63. Kwong AD, Frenkel N. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proc Natl Acad Sci USA 1987; 84: 1926-1930. (Pubitemid 17054122)
64. Oroskar AA, Read GS. Control of mRNA stability by the virion host shutoff function of herpes simplexvirus. J Virol 1989; 63: 1897-1906. (Pubitemid 19107783)
65. Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley CE et al. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs-HSV vectors for dendritic cell-mediated immunotherapy J Virol 2003; 77: 3768-3776. (Pubitemid 36297295)
66. Smith TJ, Morrison LA, Leib DA. Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J Virol 2002; 76: 2054-2061. (Pubitemid 34150673)
67. Strelow LI, Leib DA. Roleof thevirion hostshutoff (vhs) of herpessimplexvirustype 1 in latency and pathogenesis. J Virol 1995; 69: 6779-6786.
68. Dudek T, Mathews LC, Knipe DM. Disruption of the U(L)41 gene in theherpessimplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008; 372: 165-175. (Pubitemid 351215459)
69. Geiss BJ, Smith TJ, Leib DA, Morrison LA. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpessimplexvirustype 1 vaccinestrain. J Virol 2000; 74: 11137-11144. (Pubitemid 32223980)
70. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplexvirus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008; 26: 4034-4040.
71. Everly Jr DN, Read GS. Mutational analysis of the virion host shutoff gene (UL41) of herpes simplexvirus (HSV): characterization of HSVtype 1 (HSV-1)/HSV-2 chimeras. J. Virol 1997; 71: 7157-7166. (Pubitemid 27391649)
72. Reszka NJ, Dudek T, Knipe DM. Construction andproperties of a herpes simplexvirus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010; 28: 2754-2762.
73. Murphy CG, Lucas WT, Means RE, Czajak S, Hale CL, Lifson JD et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplexvirus. J Virol 2000; 74: 7745-7754. (Pubitemid 30641618)
74. Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D et al. Ability of herpes simplexvirusvectorsto boost immuneresponsesto DNAvectorsandto protectagainst challenge by simian immunodeficiencyvirus. Virology 2007; 357: 199-214. (Pubitemid 44830064)
75. Samaniego LA, Neiderhiser L, Deluca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320. (Pubitemid 28175576)
76. Watanabe D, Brockman MA, Ndung'u T, Mathews L, Lucas WT, Murphy CG et al. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombi-nantasavaccinevector. Virology 2007; 357: 186-198. (Pubitemid 44821300)
77. Liu X, Broberg E, Watanabe D, Dudek T, Deluca N, Knipe DM. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 2009; 27: 2760-2767.
78. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266. (Pubitemid 120031840)
79. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843-848.
80. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90 000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516-10520. (Pubitemid 3009119)
81. Jagus R, Joshi B, Barber GN. PKR, apoptosis and cancer. Int J Biochem Cell Biol 1999; 31: 123-138. (Pubitemid 29094794)
82. Rosenwald IB. The roleof translation in neoplastictransformation from a pathologist's point of view. Oncogene 2004; 23: 3230-3247. (Pubitemid 38638835)
83. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK et al. Aherpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276-283. (Pubitemid 19268271)
84. Goldstein DJ, Weller SK. Herpes simplexvirustype 1-induced ribonucleotide reduc-tase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205. (Pubitemid 18050809)
85. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166: 41-51.
86. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
87. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874. (Pubitemid 30303584)
88. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
89. Mohr I, Gluzman Y A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBOJ 1996; 15:4759-4766. (Pubitemid 26294594)
90. He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, Roizman B. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049-6054. (Pubitemid 27304944)
91. Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998; 72: 7005-7011. (Pubitemid 28377827)
92. Cassady KA, Gross M, Roizman B. The herpes simplexvirus US11 protein effectively compensatesforthegamma1(34.5) gene if present beforeactivation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 1998; 72: 8620-8626. (Pubitemid 28471800)
93. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401. (Pubitemid 32488248)
94. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplexvirus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res 2005; 11: 7886-7890. (Pubitemid 41611635)
95. Taneja S, MacGregor J, Markus S, Ha S, Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804-8808. (Pubitemid 32678108)
96. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y. A herpes simplex virus type 1 gamma34.5S-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189-5196. (Pubitemid 32448541)
97. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303. (Pubitemid 36305598)
98. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplexvirus as an insitucancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-393. (Pubitemid 29097317)
99. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplexvirus. Hum Gene Ther 1999; 10: 2741-2755.
100. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195: 346-355. (Pubitemid 36529863)
101. van Hall T, Wolpert EZ, van VP, Laban S, van dV, Roseboom M et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006; 12: 417-424.
102. Chambers B, Grufman P, Fredriksson V, Andersson K, Roseboom M, Laban S et al. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res 2007; 67: 8450-8455. (Pubitemid 47437417)
103. Wolpert EZ, Petersson M, Chambers BJ, Sandberg JK, Kiessling R, Ljunggren HG et al. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci USA 1997; 94: 11496-11501. (Pubitemid 27451027)
104. Oliveira CC, van Veelen PA, Querido B, de RA, Sluijter M, Laban S et al. The nonpolymorphic MHC Qa-1b mediates CD8+ Tcell surveillanceof antigen-processing defects. J Exp Med 2010; 207: 207-221.
105. van Hall T, Laban S, Koppers-Lalic D, Koch J, Precup C, Asmawidjaja P et al. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes byQa-1b1. J Immunol 2007; 178: 657-662. (Pubitemid 46095137)
106. Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J et al. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci USA 2005; 102: 5144-5149.
107. Schagen FH, Ossevoort M, Toes RE, Hoeben RC. Immune responses against adeno-viral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 2004; 50: 51-70. (Pubitemid 38501617)
108. Zaldumbide A, Hoeben RC. How not to be seen: immune-evasion strategies in gene therapy. Gene Ther 2008; 15: 239-246. (Pubitemid 351223460)
109. Berger C, Xuereb S, Johnson DC, Watanabe KS, Kiem HP, Greenberg PD et al. Expression of herpes simplexvirus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes. J Virol 2000; 74: 4465-4473. (Pubitemid 30237871)
110. Scaria A, Sullivan JA, St George JA, Kaplan JM, Lukason MJ, Morris JE et al. Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lympho-cytes in nonhuman primates. Mol Ther 2000; 2: 505-514.
111. Ossevoort M, Zaldumbide A, Cramer SJ, van der Voort EI, Toes RE, Hoeben RC. Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinasegene. Cancer Gene Ther 2006; 13: 584-591.
112. Ossevoort M, Visser BM, van den Wollenberg DJ, van d V, Offringa R, Melief CJ et al. Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther 2003; 10: 2020-2028. (Pubitemid 37407098)
113. Hendriks WT, Eggers R, Carlstedt TP, Zaldumbide A, Tannemaat MR, Fallaux FJ et al. Lentiviral vector-mediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune 'stealth' transgene. Restor Neurol Neurosci 2007; 25: 585-599. (Pubitemid 351525720)
114. Burgert HG, Kvist S. An adenovirustype 2 glycoprotein blocks cell surface expression of human histocompatibilityclass I antigens. Cell 1985; 41: 987-997. (Pubitemid 15243402)
115. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985; 43: 215-222. (Pubitemid 16199707)
116. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999; 162: 5049-5052. (Pubitemid 29307102)
117. Sester M, Koebernick K, Owen D, Ao M, Bromberg Y, May E et al. Conserved amino acids within the adenovirus 2 E3/19K protein differentially affect downregulation of MHC class I and MICA/B proteins. J Immunol 2010; 184: 255-267.
118. Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunor-egulatory cell proteins. JGene Med 2004; 6(Suppl 1): S172-S183. (Pubitemid 40228026)
119. Windheim M, Hilgendorf A, Burgert HG. Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways. Curr Top Microbiol Immunol 2004; 273: 29-85. (Pubitemid 37203631)
120. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, Elsing A. Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 2002; 269: 273-318. (Pubitemid 34851538)
121. Kojaoghlanian T, Joseph A, Follenzi A, Zheng JH, Leiser M, Fleischer N et al. Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice. Gene Ther 2009; 16: 340-348.
122. Efrat S, Fejer G, Brownlee M, Horwitz MS. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci USA 1995; 92: 6947-6951.
123. Oosten LE, Koppers-Lalic D, Blokland E, Mulder A, Ressing ME, Mutis T et al. TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibilityantigen-specific recognition bycytotoxic T lymphocytes. Int Immu-nol 2007; 19: 1115-1122. (Pubitemid 47434244)
124. Lee EM, Kim JY, Cho BR, Chung WK, Yoon BW, Kim SU et al. Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochem Biophys Res Commun 2005; 326: 825-835. (Pubitemid 39655994)
125. Kim JY, Kim D, Choi I, Yang JS, Lee DS, Lee JR et al. MHC expression in a human adult stem cell line and its down-regulation by hCMV US gene transfection. Int J Biochem Cell Biol 2005; 37: 69-78. (Pubitemid 39286025)
126. Crew MD, Phanavanh B. Exploiting virus stealth technology for xenotransplantation: reduced human T cell responses to porcine cells expressing herpes simplex virus ICP47. Xenotransplantation 2003; 10: 50-59. (Pubitemid 36908957)